2. Search Result
Search Result
Results for "

20-HETE

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

2

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156876
    20-HETE inhibitor-2

    		Others Metabolic Disease
    GPR75 antagonist-2 is an antagonist of GPR75. GPR75 antagonist-2 can used in study obesity and insulin resistance .
    20-HETE inhibitor-2
  • HY-15598S
    20-HETE-d6

    20-Hydroxyarachidonic acid-d6; 20-Hydroxyeicosatetraenoic acid-d6

    		 Isotope-Labeled Compounds Others
    20-HETE-d6 is the deuterium labeled 20-HETE[1].
    20-HETE-d6
  • HY-121188
    DDMS

    Dibromo-dodecenyl-methylsulfimide

    		 Cytochrome P450 Cardiovascular Disease
    DDMS (Dibromo-dodecenyl-methylsulfimide) is a selective 20-HETE production inhibitor. DDMS attenuates the vasodilatory response to sodium nitroprusside (SNP) .
    DDMS
  • HY-124527
    HET0016
    2 Publications Verification

    		 Cytochrome P450 Cardiovascular Disease
    HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth .
    HET0016
  • HY-101527
    20-HEDE
    2 Publications Verification

    WIT 002

    		 Others Cancer
    20-HEDE (WIT 002) is an antagonist of 20-hydroxyeicosatetraenoic acid (20-HETE).
    20-HEDE
  • HY-148226
    20-5,14-HEDGE

    		Others Cardiovascular Disease
    20-5,14-HEDGE is a 20-HETE analog. 20-5,14-HEDGE protects against lung ischemic reperfusion injury in rats .
    20-5,14-HEDGE
  • HY-160187
    AAA

    		Others Cardiovascular Disease
    AAA is a potent blocker of 20-Hydroxyeicosatetraenoic acid (20-HETE) receptor that binds directly to GPR75 and prevents the increases in intracellular Ca2+, IP-1 and β-arrestin .
    AAA
  • HY-156875
    20-HETE inhibitor-1

    		Cytochrome P450 Others
    20-HETE inhibitor-1 (comp 83) is a 20-HETE formation inhibitor
    20-HETE inhibitor-1
  • HY-113516
    20-HETE Ethanolamide

    		Endogenous Metabolite Neurological Disease
    20-HETE Ethanolamide is a metabolite of endocannabinoid Anandamide. 20-HETE Ethanolamide binds to the rat brain cannabinoid CB1 receptor with a Ki of 985 nM .
    20-HETE Ethanolamide
  • HY-139114
    20-Carboxyarachidonic acid

    		PPAR Metabolic Disease
    20-Carboxyarachidonic acid, a relatively stable metabolite of 20-HETE, is an endogenous dual activator of PPARalpha and PPARgamma .
    20-Carboxyarachidonic acid
  • HY-101016
    17-ODYA

    		Cytochrome P450 Apoptosis Cardiovascular Disease
    17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes . 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    17-ODYA
  • HY-149770
    CYP4A11/CYP4F2-IN-2

    		Cytochrome P450 Metabolic Disease
    CYP4A11/CYP4F2-IN-2 (compound 15) is an orally available inhibitor of CYP4A11/4F2 with IC50s of 120 nM and 220 nM, respectively. CYP4A11/CYP4F2-IN-2 inhibits 20-HETE production in rat kidney and has potential inhibitory effects on diabetic nephropathy and autosomal dominant polycystic kidney disease .
    CYP4A11/CYP4F2-IN-2
  • HY-160186
    20-SOLA

    		Others Cardiovascular Disease
    20-SOLA is the first water soluble and orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a streptozotocin (STZ (HY-13753))-diabetic mouse model. 20-SOLA also is a GPR75 receptor blocker. 20-SOLA can be used for the research of cardiovascular pathologies .
    20-SOLA
  • HY-160099
    20-5,14-HEDE

    		Apoptosis Caspase DNA/RNA Synthesis Cardiovascular Disease
    20-5,14-HEDE is an analog of 20-HETE with anti-apoptosis activity. 20-5,14-HEDE can inhibit the increase of caspase-3 expression level and DNA fragmentation in pulmonary artery endothelial cells (BPAECs) under serum starvation conditions, thereby reducing cell apoptosis. 20-5,14-HEDE can be used in the study of cardiovascular diseases .
    20-5,14-HEDE
  • HY-151809
    CYP4A11/CYP4F2-IN-1

    		Cytochrome P450 Metabolic Disease
    CYP4A11/CYP4F2-IN-1 is a potent dual inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2, with IC50s of 19 nM and 17 nM, respectively. CYP4A11/CYP4F2-IN-1 has potential for the research of renal diseases .
    CYP4A11/CYP4F2-IN-1
  • HY-151810
    TP0472993

    		Cytochrome P450 Metabolic Disease
    CYP4A11/CYP4F2-IN-2 is a potent and orally active dual inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2, with IC50s of 140 nM and 40 nM, respectively. CYP4A11/CYP4F2-IN-2 has potential for the research of renal diseases .
    TP0472993

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: